The  ||| S:0 E:4 ||| DT
role  ||| S:4 E:9 ||| NN
of  ||| S:9 E:12 ||| IN
home  ||| S:12 E:17 ||| NN
palliative  ||| S:17 E:28 ||| NN
care  ||| S:28 E:33 ||| NN
by  ||| S:33 E:36 ||| IN
health  ||| S:36 E:43 ||| NN
insurance  ||| S:43 E:53 ||| NN
pharmacy  ||| S:53 E:62 ||| VBD
Our  ||| S:62 E:66 ||| PRP$
Pharmacy  ||| S:66 E:75 ||| NNP
has  ||| S:75 E:79 ||| VBZ
been  ||| S:79 E:84 ||| VBN
practicing  ||| S:84 E:95 ||| VBG
pharmaceutical  ||| S:95 E:110 ||| JJ
management  ||| S:110 E:121 ||| NN
guidance  ||| S:121 E:130 ||| NN
for  ||| S:130 E:134 ||| IN
69  ||| S:134 E:137 ||| CD
homecare  ||| S:137 E:146 ||| CD
patients  ||| S:146 E:155 ||| NNS
in  ||| S:155 E:158 ||| IN
the  ||| S:158 E:162 ||| DT
last  ||| S:162 E:167 ||| JJ
13  ||| S:167 E:170 ||| CD
years ||| S:170 E:175 ||| NNS
.  ||| S:175 E:177 ||| .
After  ||| S:177 E:183 ||| IN
we  ||| S:183 E:186 ||| PRP
started  ||| S:186 E:194 ||| VBD
a  ||| S:194 E:196 ||| DT
home  ||| S:196 E:201 ||| NN
parenteral  ||| S:201 E:212 ||| NN
nutrition  ||| S:212 E:222 ||| NN
service ||| S:222 E:229 ||| NN
,  ||| S:229 E:231 ||| ,
an  ||| S:231 E:234 ||| DT
opportunity  ||| S:234 E:246 ||| NN
to  ||| S:246 E:249 ||| TO
work  ||| S:249 E:254 ||| VB
with  ||| S:254 E:259 ||| IN
the  ||| S:259 E:263 ||| DT
end-stage  ||| S:263 E:273 ||| JJ
cancer  ||| S:273 E:280 ||| NN
patient  ||| S:280 E:288 ||| NN
was  ||| S:288 E:292 ||| VBD
increased ||| S:292 E:301 ||| VBN
.  ||| S:301 E:303 ||| .
To  ||| S:303 E:306 ||| TO
contribute  ||| S:306 E:317 ||| VB
to  ||| S:317 E:320 ||| TO
the  ||| S:320 E:324 ||| DT
patient  ||| S:324 E:332 ||| NN
and  ||| S:332 E:336 ||| CC
community  ||| S:336 E:346 ||| NN
health  ||| S:346 E:353 ||| NN
team ||| S:353 E:357 ||| NN
,  ||| S:357 E:359 ||| ,
we  ||| S:359 E:362 ||| PRP
have  ||| S:362 E:367 ||| VBP
practiced  ||| S:367 E:377 ||| VBN
pharmaceutical  ||| S:377 E:392 ||| JJ
management  ||| S:392 E:403 ||| NN
guidance  ||| S:403 E:412 ||| NN
for  ||| S:412 E:416 ||| IN
homecare  ||| S:416 E:425 ||| JJ
patient  ||| S:425 E:433 ||| NN
based  ||| S:433 E:439 ||| VBN
on  ||| S:439 E:442 ||| IN
the  ||| S:442 E:446 ||| DT
medical  ||| S:446 E:454 ||| JJ
and  ||| S:454 E:458 ||| CC
pharmacology  ||| S:458 E:471 ||| JJ
point  ||| S:471 E:477 ||| NN
of  ||| S:477 E:480 ||| IN
view  ||| S:480 E:485 ||| NN
with  ||| S:485 E:490 ||| IN
other  ||| S:490 E:496 ||| JJ
area  ||| S:496 E:501 ||| NN
of  ||| S:501 E:504 ||| IN
occupational  ||| S:504 E:517 ||| JJ
people ||| S:517 E:523 ||| NNS
.  ||| S:523 E:525 ||| .
We  ||| S:525 E:528 ||| PRP
distributed  ||| S:528 E:540 ||| VBD
a  ||| S:540 E:542 ||| DT
pain  ||| S:542 E:547 ||| NN
diary  ||| S:547 E:553 ||| NNS
and  ||| S:553 E:557 ||| CC
medical  ||| S:557 E:565 ||| JJ
usage  ||| S:565 E:571 ||| NN
of  ||| S:571 E:574 ||| IN
drug  ||| S:574 E:579 ||| NN
guidance  ||| S:579 E:588 ||| NN
to  ||| S:588 E:591 ||| TO
the  ||| S:591 E:595 ||| DT
end-stage  ||| S:595 E:605 ||| JJ
cancer  ||| S:605 E:612 ||| NN
outpatients ||| S:612 E:623 ||| NN
.  ||| S:623 E:625 ||| .
We  ||| S:625 E:628 ||| PRP
also  ||| S:628 E:633 ||| RB
made  ||| S:633 E:638 ||| VBN
a  ||| S:638 E:640 ||| DT
drug  ||| S:640 E:645 ||| NN
instructional  ||| S:645 E:659 ||| JJ
manual  ||| S:659 E:666 ||| NN
and  ||| S:666 E:670 ||| CC
provided  ||| S:670 E:679 ||| VBD
a  ||| S:679 E:681 ||| DT
proper  ||| S:681 E:688 ||| JJ
prescription  ||| S:688 E:701 ||| NN
to  ||| S:701 E:704 ||| TO
the  ||| S:704 E:708 ||| DT
patient ||| S:708 E:715 ||| NN
.  ||| S:715 E:717 ||| .
Because  ||| S:717 E:725 ||| IN
of  ||| S:725 E:728 ||| IN
our  ||| S:728 E:732 ||| PRP$
efforts ||| S:732 E:739 ||| NNS
,  ||| S:739 E:741 ||| ,
we  ||| S:741 E:744 ||| PRP
believe  ||| S:744 E:752 ||| VBP
that  ||| S:752 E:757 ||| IN
we  ||| S:757 E:760 ||| PRP
had  ||| S:760 E:764 ||| VBD
good  ||| S:764 E:769 ||| JJ
consistent  ||| S:769 E:780 ||| JJ
results  ||| S:780 E:788 ||| NNS
from  ||| S:788 E:793 ||| IN
the  ||| S:793 E:797 ||| DT
end-stage  ||| S:797 E:807 ||| JJ
cancer  ||| S:807 E:814 ||| NN
outpatients ||| S:814 E:825 ||| NN
.  ||| S:825 E:827 ||| .
On  ||| S:827 E:830 ||| IN
the  ||| S:830 E:834 ||| DT
other  ||| S:834 E:840 ||| JJ
hand ||| S:840 E:844 ||| NN
,  ||| S:844 E:846 ||| ,
we  ||| S:846 E:849 ||| PRP
have  ||| S:849 E:854 ||| VBP
a  ||| S:854 E:856 ||| DT
lot  ||| S:856 E:860 ||| NN
of  ||| S:860 E:863 ||| IN
problems  ||| S:863 E:872 ||| NNS
that  ||| S:872 E:877 ||| WDT
have  ||| S:877 E:882 ||| VBP
to  ||| S:882 E:885 ||| TO
be  ||| S:885 E:888 ||| VB
resolved ||| S:888 E:896 ||| VBN
.  ||| S:896 E:898 ||| .
They  ||| S:898 E:903 ||| PRP
are  ||| S:903 E:907 ||| VBP
associated  ||| S:907 E:918 ||| VBN
with  ||| S:918 E:923 ||| IN
medical  ||| S:923 E:931 ||| JJ
treatment  ||| S:931 E:941 ||| NN
fee ||| S:941 E:944 ||| NN
,  ||| S:944 E:946 ||| ,
drug  ||| S:946 E:951 ||| NN
dispensing  ||| S:951 E:962 ||| NN
fee ||| S:962 E:965 ||| NN
,  ||| S:965 E:967 ||| ,
pharmacy  ||| S:967 E:976 ||| JJ
management  ||| S:976 E:987 ||| NN
pressure  ||| S:987 E:996 ||| NN
felt  ||| S:996 E:1001 ||| VBD
from  ||| S:1001 E:1006 ||| IN
a  ||| S:1006 E:1008 ||| DT
low  ||| S:1008 E:1012 ||| JJ
dispensing  ||| S:1012 E:1023 ||| JJ
fee ||| S:1023 E:1026 ||| NN
,  ||| S:1026 E:1028 ||| ,
poor  ||| S:1028 E:1033 ||| JJ
quality  ||| S:1033 E:1041 ||| NN
stocked  ||| S:1041 E:1049 ||| VBN
narcotic  ||| S:1049 E:1058 ||| JJ
drugs  ||| S:1058 E:1064 ||| NNS
and  ||| S:1064 E:1068 ||| CC
a  ||| S:1068 E:1070 ||| DT
low  ||| S:1070 E:1074 ||| JJ
recognition  ||| S:1074 E:1086 ||| NN
of  ||| S:1086 E:1089 ||| IN
the  ||| S:1089 E:1093 ||| DT
pharmacist  ||| S:1093 E:1104 ||| NN
from  ||| S:1104 E:1109 ||| IN
the  ||| S:1109 E:1113 ||| DT
patients  ||| S:1113 E:1122 ||| NNS
and  ||| S:1122 E:1126 ||| CC
regional  ||| S:1126 E:1135 ||| JJ
community  ||| S:1135 E:1145 ||| NN
medical  ||| S:1145 E:1153 ||| JJ
team ||| S:1153 E:1157 ||| NN
.  ||| S:1157 E:1159 ||| .
We  ||| S:1159 E:1162 ||| PRP
believe  ||| S:1162 E:1170 ||| VBP
that  ||| S:1170 E:1175 ||| IN
we  ||| S:1175 E:1178 ||| PRP
can  ||| S:1178 E:1182 ||| MD
contribute  ||| S:1182 E:1193 ||| VB
more  ||| S:1193 E:1198 ||| JJR
to  ||| S:1198 E:1201 ||| TO
the  ||| S:1201 E:1205 ||| DT
patients ||| S:1205 E:1213 ||| NNS
,  ||| S:1213 E:1215 ||| ,
if  ||| S:1215 E:1218 ||| IN
we  ||| S:1218 E:1221 ||| PRP
can  ||| S:1221 E:1225 ||| MD
overcome  ||| S:1225 E:1234 ||| VB
these  ||| S:1234 E:1240 ||| DT
problems ||| S:1240 E:1248 ||| NNS
.  ||| S:1248 E:1250 ||| .
